by Alex Kadhim
Researchers from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) conducted the PHYLOS trial and found that posttransplant cyclophosphamide (PTCy)-based prophylaxis significantly reduces the...
by ASTCT Talks
An expert panel highlights key presentations in multiplemyeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.
CancerNetwork®, in collaboration with The...
by Alex Kadhim
Researchers from the National Cancer Institute (NCI), USA, have demonstrated that intermediate-dose post-transplantation cyclophosphamide (ID-PTCy) at 25 mg/kg/day administered on days 3 and 4...
by Alex Kadhim
Researchers from Stanford University have demonstrated that administering precision-selected donor regulatory T-cell (Treg) therapy significantly improves graft-versus-host disease-free,...
by ASTCT Talks
In this episode of ASTCT Talks, Dr. Taha Al-Juhaishi welcomes Dr. Marcos de Lima, hematologist-oncologist at The OhioState University Comprehensive Cancer Center, to explore the rapidly evolving...
by Alex Kadhim
Researchers from the University of Minnesota have demonstrated that individualized dosing of rabbit anti-thymocyte globulin (rATG), based on recipient bodyweight and absolute lymphocyte count...